BESPONSA INJECTION 1MG SPECIAL INVESTIGATION (PEDIATRIC INVESTIGATION)
Latest Information Update: 29 Nov 2024
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Pfizer
- 27 Nov 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 24 Sep 2024 Planned number of patients changed from 29 to 1.
- 24 Sep 2024 Planned initiation date changed from 23 Jul 2024 to 31 Dec 2024.